Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00149877|
Recruitment Status : Completed
First Posted : September 8, 2005
Last Update Posted : February 1, 2008
|Condition or disease||Intervention/treatment||Phase|
|Chronic Constipation||Drug: Tegaserod||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||250 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation|
|Study Start Date :||April 2004|
|Actual Study Completion Date :||February 2006|
- Number of complete spontaneous bowel movement (csbm) during the first 4 weeks of treatment.
- Number of csbm during 8 weeks of treatment.
- Daily assessment of bowel habits:frequency, form, straining, feeling of complete evacuation.
- Daily patients' assessment: bowel habits, constipation, distention/bloating, abdominal discomfort pain.
- Laxative use.
- Safety and tolerability.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00149877
|Basel, Switzerland, 4056|